{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Kandinov B"],"funding":["Moderna, Inc"],"pubmed_abstract":["The safety, immunogenicity, and efficacy of the original formulation of the investigational mRNA-1010 vaccine for seasonal influenza were investigated in two randomized, active-controlled, phase 3 trials in adults (NCT05415462 and NCT05566639), and the results were used to evaluate hemagglutination inhibition (HAI) titers as correlates of risk and protection against influenza-like illness. mRNA-1010 (50-µg) demonstrated an acceptable reactogenicity and safety profile among the >14,000 adult participants vaccinated in both trials. The efficacy profile of mRNA-1010 was generally reflective of immunogenicity findings, with higher immune responses against influenza A strains and lower responses against influenza B strains relative to an active comparator (licensed inactivated influenza vaccine"],"journal":["Human vaccines & immunotherapeutics"],"pagination":["2484088"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11970786"],"repository":["biostudies-literature"],"pubmed_title":["An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers."],"pmcid":["PMC11970786"],"pubmed_authors":["Hall K","Fierro C","Ananworanich J","Miller J","Soens M","Avanesov A","Kandinov B","Nachbagauer R","Llapur C","Rudden S","Schaefers K","Ma C","Park Y","Guo J","Essink B","Huang W","Ensz D","Du E","Zheng L","Zhou H","Vakil J","Pucci A","Hicks B"],"additional_accession":[]},"is_claimable":false,"name":"An mRNA-based seasonal influenza vaccine in adults: Results of two phase 3 randomized clinical trials and correlate of protection analysis of hemagglutination inhibition titers.","description":"The safety, immunogenicity, and efficacy of the original formulation of the investigational mRNA-1010 vaccine for seasonal influenza were investigated in two randomized, active-controlled, phase 3 trials in adults (NCT05415462 and NCT05566639), and the results were used to evaluate hemagglutination inhibition (HAI) titers as correlates of risk and protection against influenza-like illness. mRNA-1010 (50-µg) demonstrated an acceptable reactogenicity and safety profile among the >14,000 adult participants vaccinated in both trials. The efficacy profile of mRNA-1010 was generally reflective of immunogenicity findings, with higher immune responses against influenza A strains and lower responses against influenza B strains relative to an active comparator (licensed inactivated influenza vaccine","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-02T17:32:43.043Z","creation":"2025-07-08T03:13:01.512Z"},"accession":"S-EPMC11970786","cross_references":{"pubmed":["40174609"],"doi":["10.1080/21645515.2025.2484088"]}}